Halozyme Therapeutics (HALO) Stock News
$HALO · NASDAQ · 7 stories in 30 days$120.75
1D −0.63%1W +0.51%1M +3.20%
BORSA has published 7 stories on Halozyme Therapeutics (HALO) in the past 30 days, 2 of them high impact. BORSA’s news read on HALO is mixed at 52/100, −3 over 24 hours, based on 2 company events over the past 7 days. HALO last closed at $110.42 on Oct 9, up 0.51% over five sessions and up 3.20% over the past month. Halozyme Therapeutics’ next earnings report is scheduled for Monday, Nov 2.
The wire on $HALO
newest first · updated · direct subject stories onlyTD Cowen lifts Halozyme Therapeutics price target to $130.00
TD Cowen increased its price target for Halozyme Therapeutics from $105.00 to $130.00 per share.
bullish 70 · impact 30Insider transactions for week ended Oct 9: Halozyme CEO, United Therapeutics chair sell shares
Insider transactions for week ended Oct 9: Halozyme CEO, United Therapeutics chair sell shares.
neutral 50 · impact 20
